You are here

VRTX

$150.13

-1.27%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Apr 27, 2017
-First-quarter 2017 cystic fibrosis product revenues of $481 million; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million- ...